Liarozole fumarate (R85246): A novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 59, Issue 1, 2000, Pages 55-68

  Goss, Paul E ^a,b   Oza, Amit ^b   Goel, Rakesh ^c   Nabholtz, Jean Marc ^d   De Coster, Roland ^e   Bruynseels, Jan ^e   Reid, Caroline ^a   Wadden, Nancy ^a   Crump, Michael ^a   Tye, Lesley M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Liarozole; Metastatic breast cancer; Postmenopausal

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; LIAROZOLE FUMARATE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; EDEMA; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; MYALGIA; NAIL DISEASE; NAUSEA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; REMISSION; RETINOL INTOXICATION; TASTE DISORDER; VOMITING; XEROPHTHALMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGENS; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; RECEPTORS, ESTROGEN; SKIN DISEASES;

EID: 0034023928     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006320122711     Document Type: Article

References (43)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 3: 104-107, 1986
2. Henderson IC: Endocrine therapy in metaslatic breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. JB Lippincott, Philadelphia, 1987, 421 p
3. Kostraba N, Kiang D, Frenning D, Theologides A, Kennedy BJ: Multiple endocrine therapy in the management of advanced breast cancer. (Abstract #586) Proc Am Assoc Cancer Res 21: 147, 1980
4. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eirmann W, Wolter JM, Azab M, Webster A, Plourde PV for the Arimidex Study Group: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in post-menopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14: 2000-2011, 1996
5. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Harschek T, Tjabbes T, Chaudri HA, Homberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998
6. Taylor SG, Gelman RS, Falkson G, Cummings FJ: Combination chemotherapy compared to tamoxifen as initial therapy for Stage IV breast cancer in elderly women. Ann Int Med 104: 455-461, 1986
7. Mahler C, Verhelst J, Denis L: Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 71: 1068-1073, 1993
8. Dijkman GA, Fernandez, del Moral P, Bruynseels J, De Porre P, Denis L, Debruyne FMJ: Liarozole (R75251) in hormone-resistant prostate cancer patients. Prostate 33: 26-31, 1997
9. Wouters W, van Dun J, Dillen A, Coene M-C, Cools W, De Coster R: Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 52: 2841-2846, 1992
10. Van heusden J , Borgers M, Ramaekers F, Xhonneux B, Wouters W, De Coster R, Smets, G: Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro. Eur J Cell Biol 71: 89-98, 1996
11. Koymans LMH, Moereels H, Vanden Bossche H: A molecular model for the interaction between vorozole and other non-steroidal inhibitors and human cytochrome P450 19 (P450 aromatase). J Steroid Biochem Molec Biol 53 (1-6): 191-197, 1995
12. Bruynseels J, De Coster R, Van Rooy P, Wouters W, Coene M-C, Snoeck E, Raeymaekers A, Freyne E, Sanz. G, Vanden Bossehe G, Vanden Bossche H, Willemsens G, Janssen, PAJ: R75251, a new inhibitor of steroid biosynthesis. Prostate 16: 345-357, 1990
13. Van Wauwe JP, Coene M-C, Goossens J, Cools W, Monbaliu J: Effects of cytochrome P450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 252: 365-369, 1990
14. Van Wauwe J, Van Nyen G, Coene M-C, Stoppie P, Cools W, Goossens J, Borghgraef P, Janssen PAJ: Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 261: 773-779, 1992
15. Van Wauwe J, Coene M-C, Cools W, Goosens J, Lauwers W, Le Jeune L, Van Hove CW, Van Nyen G: Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem Pharmacol 47: 737-741, 1994
16. End D, Wouters W, Garrabrant T, Bowden C, De Coster R, Van Ginckel R: Anti-tumor effects of liarozole in TA3 mammary carcinoma: comparison to retinoic acid. (Abstract #158) Proc Am Assoc Cancer Res 33: 27, 1992
17. Liarozole Investigator's Brochure, 3rd edition, August, 1994
18. Fishman B, Pastrnak S, Wallenstein SL, Houde RW, Holland JC, Foley KM: The Memorial Pain Assessment Card: a valid instrument for the measurement of cancer pain. Cancer 60: 1151-1157, 1987
19. World Health Organization. Cancer Pain Relief, Geneva, 1986
20. Schipper H, Clinch J, McMurray A, Levitt M: Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2: 472-483, 1984
21. World Health Organization, 1979. Handbook for reporting results of cancer treatment. Offset Publication No. 48 WHO, Geneva, 1979
22. De Coster R, Beerens D, Dom J, Willemsens G: Endocrinological effects of single daily ketoconazole therapy in male beagle dogs. Acta Endocrinol 107: 275-281, 1984
23. De Coster R, Caers I, Coene M-C, Amery W, Beerens D, Haelterman C: Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol 24: 657-664, 1986
24. Woestenborghs R, Prinsen P, Embrechts; L, Van Rompaey F, Heykants J: HPLC-fluorescence method for the determination of R075251 in plasma and animal tissues. Janssen Research Foundation, September 1989, Preclinical Research Report R06140513
25. Iveson TJ, Ahem J, Smith IE: Response to third-line endocrine treatment for advanced breast cancer. Eur J Cancer 29A: 572-574, 1993
26. Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Pommatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D: Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Br Cancer Res Treat 24: 139-145, 1992
27. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, Germe Jr DH, Loprinzi CL, Hatfield AK, Hartmann LC: A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 80(2): 218-224, 1997
28. Lundgren S, Kvinnsland S, Utaaker E: Oral high-dose progestins as treatment for advanced breast cancer. Acta Oncol 28: 811-816, 1989
29. Conte CC, Nemoto T, Rosner D, Dao TL: Therapeutic oophorectomy in metastatic breast cancer. Cancer 64: 150-153, 1989
30. Donkx P, Deree J, Degreef H: Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 133: 426-132, 1995
31. Lucker GPH, Heremans AMC, Boegheim PJ, Van de Kerkhof PCM, Steijlen PM: Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 136: 71-75, 1997
32. De Coster R, Wouters W, Bruynseels J: P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem 56: 133-143, 1996
33. Alexieva-Figuseh J, Blankenstein MA, Hop WCJ, Klijn JGM, Lamberts SWJ, De Jong FH, Doeter R, Adlercreutz H, Van Gilse HA: Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects. Eur J Cancer Clin Oncol 20: 33-40, 1984
34. Santen RJ, Wells SA, Cohn N, Demers LM, Misbin RI, Foltz EL: Compensatory increase in TSH secretion without effects on prolactin secretion in patients treated with aminoglutethimide. J Clin Endocrinol Metab 45: 739-746, 1977
35. Rallison ML, Kumagai LF, Tyler FH: Goitrous hypothyroidism induced by aminoglutethimide, anticonvusant drug. J Clin Endocr 27: 265-272, 1967
36. Lippman ME, Dickson RB: Mitogenic regulation of normal and malignant breast epithelium. Yale J Biol Med 62: 459-480, 1989
37. Pollak MN, Huynh HT, Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Br Cancer Res Treat 22: 91-100, 1992
38. Helle SI, Holly JMP, Tally M, Hall K, Vander Stappen J, Lonning PE: Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69: 335-339, 1996
39. Bentel JM, Lebwohl DE, Cullen KJ, Rubin MS. Rosen N, Mendelsohn J, Miller Jr WH: Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells. J Cell Physiol 165: 212-221, 1995
40. Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A: Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Br Cancer Res Treat 33: 83-88, 1994
41. Aydiner A. Topuz E, Disci R, Yasasever V, Dineer M, Dincol K, Bilge N: Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncol 33: 181-186, 1994
42. Seidmon EJ, Trump DL, Kreis W, Hall SW, Kurman MR, Ouyang SP, Wu J, Kremer AB: Phase I/II dose-escalation-study of liarozole in patients with stage D2 hormone-refractory carcinoma of the prostate. Ann Surg Oncol 2: 550-556, 1995
43. 3, (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific. J Steroid Biochem Molec Biol 57: 197-202, 1996